Open AccessCoronary Artery Calcification ( CAC ) and Post‐Trial Cardiovascular Events and Mortality Within the Women's Health Initiative ( WHI ) Estrogen‐Alone Trial
Author(s) -
Poornima Indu G.,
Mackey Rachel H.,
Allison Matthew A.,
Manson JoAnn E.,
Carr J. Jeffrey,
LaMonte Michael J.,
Chang Yuefang,
Kuller Lewis H.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006887
Subject(s) - medicine , hazard ratio , women's health initiative , myocardial infarction , placebo , randomization , coronary artery disease , cardiology , confidence interval , randomized controlled trial , postmenopausal women , pathology , alternative medicine
Among women aged 50 to 59 years at baseline in the Women's Health Initiative (WHI) Estrogen-Alone (E-Alone) trial, randomization to conjugated equine estrogen-alone versus placebo was associated with lower risk of myocardial infarction and mortality, and, in an ancillary study, the WHI-CACS (WHI Coronary Artery Calcification Study) with lower CAC, measured by cardiac computed tomography ≈8.7 years after baseline randomization. We hypothesized that higher CAC would be related to post-trial coronary heart disease (CHD), cardiovascular disease (CVD), and total mortality, independent of baseline randomization or risk factors.